ksqtx.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $257.46MM
KSQ Therapeutics is the developer of a genome-scale precision functional genomics platform, called CRISPRomics, designed to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
12/01/2021 | Series D | $100MM | $xx.xx | $596.57MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
19,230,769
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
09/28/2018 | Series C | $80.9MM | $xx.xx | $412.51MM | Alexandria Equities, Arch Venture Partners, Baillie Gifford, Cowen Healthcare Investments, Flagship Pioneering, Invus, Lilly Asia Ventures, Polaris Partners | |
Price per Share
$xx.xx
Shares Outstanding
17,898,226
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Equities, Arch Venture Partners, Baillie Gifford, Cowen Healthcare Investments, Flagship Pioneering, Invus, Lilly Asia Ventures, Polaris Partners
|
||||||
10/02/2017 | Series B | $51MM | $xx.xx | $145.02MM | Alexandria Equities, Arch Venture Partners, Flagship Pioneering, Polaris Partners | |
Price per Share
$xx.xx
Shares Outstanding
22,566,371
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Equities, Arch Venture Partners, Flagship Pioneering, Polaris Partners
|
||||||
03/01/2017 | Series A | $25.56MM | $xx.xx | $39.32MM | Flagship Pioneering, Polaris Partners | |
Price per Share
$xx.xx
Shares Outstanding
25,560,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Flagship Pioneering, Polaris Partners
|